The Indian pharmaceutical sector has faced significant disruptions across its value chain, including the quality function, due to Covid-19. For most pharmaceutical companies, the quality function has been plagued by several challenges such as unavailability of manpower, inadequate remote working infrastructure and significant volatility in supply and demand.
The industry has taken several measures to contain the impact of the pandemic on their ongoing operations. This perspective is an analysis of these measures and their impact across the pharmaceutical companies including four key learnings for the quality function.